Biopharmx Corp (NYSEAMERICAN:BPMX) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 7,863,810 shares, a growth of 29.8% from the January 12th total of 6,056,385 shares. Approximately 7.8% of the shares of the stock are sold short. Based on an average trading volume of 8,965,603 shares, the days-to-cover ratio is presently 0.9 days.
In other news, Director Stephen Morlock acquired 330,000 shares of the stock in a transaction dated Friday, November 24th. The stock was bought at an average price of $0.15 per share, with a total value of $49,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Biopharmx (NYSEAMERICAN BPMX) opened at $0.17 on Wednesday. The firm has a market cap of $21.46, a P/E ratio of -0.62 and a beta of 1.40. Biopharmx has a 52-week low of $0.10 and a 52-week high of $0.90.
Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05).
Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research note on Friday, December 8th.
ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/biopharmx-corp-bpmx-short-interest-update.html.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.